RESEARCH SITE MANAGEMENT/COORDINATOR EXPERIENCE:
2023-Present AstraZeneca D5244C00001 CROSSING, Eosinophilic Esophagitis
2022-Present Allakos AK002-027, Urticaria
2021-Present Phathom NERD-301, Non-Erosive Gastroesophageal Reflux Disease
2021-Present Freenome FRNM-004 PREEMPT, Colorectal Cancer Prevention
2021-Present Celgene CC-93538-EE-001, Eosinophilic Esophagitis
2021-2023 Finch FIN-CDI-301 PRISM 4, C-Difficile
2021-Present Seres SERES-013, C-Difficile
2021-Present Allakos AK002-021, Eosinophilia/Duodenitis
2021-Present Allakos AK002-023, Eosinophilic Gastritis and/or Eosinophilic Duodenitis
2021-Present Alnylam ALN-HSD-001, NASH
2021-Present Genfit GFT505B-319-1, Primary Biliary Cholangitis
2021-Present Arena APD334-202, Crohn’s Disease
2020-Present Metacrine MET642-201, NASH
2020-Present Allakos AK002-016X EXT to Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
2020-Present Neurogastrx NG101-201, Gastroparesis
2020-2021 Lucid EG-CL-102, Adenocarcinoma
2020-2021 Lucid EG-CL-101, Barrett’s Esophagus
2020-Present Enanta EDP305-201, NASH
2020-Present Allakos AK002-014, Eosinophilic Esophagitis
2020-Present Allakos AK002-016, Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
2020-2021 Allakos AK002-019, Eosinophilic Gastrointestinal Diseases
2019-201 Braintree BLI4900-302, Colon Prep
2019-2023 Adare SP-1011-003, Eosinophilic Esophagitis
2019-Present Medtronics MDT18014 SODA, Gastrointestinal Disorder
2019-2021 Finch CP101-CDI-E02 PRISM Ext, C-Difficile
2019-2021 Finch CDI-001, C-difficile
2019-2021 4D Pharma BHT-II-002, IBS
2019-Present Intercept 747-304, NASH
2019-2021 Gilead GS-US-337-1431, Hepatitis C Virus
2019 Pfizer C1061011, NASH
2018-2019 Idorsia ID-078A303, Insomnia
2018-2019 Novo Nordisk EX9536-4388, Cardiovascular Outcomes “SELECT”
2018-2019 RegenLab 2014-WH-02, Diabetic foot ulcer
2018-2019 Idorsia ID-078A302, Insomnia
2018-2019 Enanta EDP 305-101, NASH
2018-2019 MedImmune D7870C00002, Stable CAD
2017-2019 The Medicines Company MDCO-PCS-17-04 “ORION-10”, Lipids
2017-2019 Pfizer B5091007, C-Diff Vaccine
2017-2019 Novo Nordisk NN9535-4270, Diabetes “SUSTAIN VIII”
2017-2018 KOWA K 877-302, Hypertriglyceridemia
2016 GSK 204682, Open-Label Extension to GLP200952, Type II Diabetes
2016-2017 Amgen 20130287, Type II Diabetes/Hypercholesterolemia
2016-2017 GSK GLP200952, Type II Diabetes
2016-2019 Esperion 1002-043, Statin-intolerant
2016-2018 Eisai, E2006-G000-304 Insomnia
2016 Bayer 17530, Diabetic Kidney Disease
2015-2016 Bayer 16244 Finerenone Diabetic Kidney Disease
2015-2016 Innocoll INN-TOP-004, Foot Ulcer
2015-2016 Regeneron R475-PN-1227, OA of the Knee/Hip
2015-2017 Actavis AV01.2015-0863, OA of the knee
2015-2018 GlaxoSmithKline GLP116174, Diabetes
2015 Next Science, CSP-003, Acne
2014-2016 Astellas, 178-MA-1005, Overactive Bladder
2014-2016 Pfizer, B1481020, Hypercholesterolemia
2013-2014 TOLMAR, TOL2680A, Acne
2013-2016 Intarcia, ITCA650-CLP-107, Diabetes/CV Outcomes2013-2014 IROKO MEL3-12-02, OA Knee/Hip
2013-2014 IROKO MEL3-12-03, OA Knee/Hip
2012-2018 Amarin AMR-01-01-0019 “REDUCE-IT”, High triglycerides
2012-2013 Merck, MK3102-018, Diabetes/CV Outcomes
2012-2015 Sanofi LTS11717, Hypercholesterolemia CV Risk
2012-2014 Ardea Biosciences, RDEA594-302 CLEAR 2, Gout
2012-2014 Ardea Biosciences, RDEA594-304 CRYSTAL 304, Gout
2011-2013 Novartis, CAIN457F2208, Rheumatoid Arthritis
2010-2011 Astra Zeneca-D5132C00001-Prevention thrombolytic events coronary event
2010-2013 GlaxoSmithKline-SB-480848/033 TIMI 52-AcuteCoronary Syndrome
2010-2011 Cardiokine-CKLX 3431-Hyponatremia
2010-2011 Merck, MK4305-028-Primary Insomnia
2009-2017 Takeda-TMX-67_301-Cardiovascular Comorbidities, Hyperuricemia, and Gout
2009-2010 Takeda-SYR-322_402-Type 2 Diabetes post coronary event
2009-2010 Cardiokine-CK-LX3430-Hyponatremia
2009-2016 Pfizer A3191172 PRECISION – Osteo/Rheumatoid Arthritis
2009-2010 Merck 431C-128- Type 2 Diabetes Mellitus
2006-2008 Abbott Labs-M05-750-Hypercholesterolemia (Lipitor)
2006-2008 Abbott Labs-M05-758-Hypercholesterolemia
2006-2008 Amgen-20050168-Rheumatoid Arthritis
2006 BMS-MB102008-Diabetes
2006-2008 Sanofi-Aventis-EFC5826-reduce cardiovascular events in obesity
2006 Sanofi -EFC5593-Diabetes
2006 Centocor-C0524T05-Rheumatoid Arthritis
2006 Centocor C0524T11-Rheumatoid Arthritis
2006 Centocor-C0743T09-Psoriasis
2006-2009 Novo Nordisk-1573-Diabetes
2006-2007 Roche-WA18696-Rheumatoid Arthritis
2006-2007 Regeneron-IL1T-AI-0505-CIAS1 Associated Periodic Syndrome
2006 Wyeth-0881A8-205-WW-Asthma
2006 Schering Plough-IMPROVE IT-Acute Coronary Syndrome
2006 ARENA, ADP125-004, Insomnia with sleep lab
2006 Velocimed, G050112, Migraine – PFO closure procedure
2006 ETHICON Pharm, 400-05-006, Urological surgery (fibrin sealant)
2005 Merck, 032 MK-0677, Hip Fracture
2005-2007 Abbott Labs, 640-0063-01 – EXACT, Stent
2005 BMS CV181-014, Diabetes
2005 Novartis, SPP100A2331, HTN
2005 Pfizer, A2171066, Diabetes
2005 AstraZeneca, D6160C00056, Diabetes questionnaire
2005 Merck, MK-020-0524A, mixed dyslipidemia
2005-2007 GSK, 105517/COR103561, HTN
2005-2006 Cipher Pharmaceuticals, TRAMCT.02.05, OA of Hip/Knee
2005-2007 OrthoMcNeill, CAPSS-334, Migraine
2005-2006 Regeneron, IL1T-CV-0503, Lipids CRP
2005-2008 Sanofi-Aventis, EFC5555, A-Fib
2005 OrthoMcNeill, CAPSS-381, Migraine
2005 Otsuka, 156-04-250, Polycystic Chronic Kidney Disease
2005 Boehringer Ingelheim, 1160.26, A-fib
2005 Lilly, H80-US-GWAY, Diabetes
2005 Hoffmann La Roche, WP18663, Rheumatoid arthritis
2005 Valentis, 934-123, PAD w/ treadmill
2005- 2007 Takeda, 01-05-TL-475-022, Hypercholesterolemia
2005- 2006 Forest, MLN-MD-04, Fibromyalgia
2005- 2006 Novartis, CLAF237A2357, Diabetes – Impaired Glucose Tolerance
2005- 2006 Novartis, SPP100A2328, Hypertenson
2005- 2006 Otsuka, 156-02-235, Hyponatremia
2005- 2007 Pfizer, A7641006, ACS- apolipoprotein
2005- 2008 GE Healthcare, MBG 312, Nuclear Imaging
2005 GlaxoSmithKline, ITI101711, DVT prevention post knee replacement
2005 Merck. 011-00. Lipids.
2005 Merck 011-00. Obesity.
2005 Merck 026-00. Lipids
2005 Merck 026-10 Lipids extension study
2005 Merck 032-00 Lipids
2005 Merck 036-00. Diabetes.
2005- 2006 Merck 077-00. Diabetes/Lipids.
2005 Amersham. WOMEN study. Ischemia evaluation.
2005- 2006 Amylin. 2592-101 PROCLAIM. CHF.
2005 AstraZeneca. GALLANT 5 Diabetes.
2005- 2006 CV Therapeutics. 5131. Stress imaging
2005- 2007 Sanofi. EFC5823. Obesity.
2005 Neurocrine. NBI-34060-MR-0501. Insomnia.
2005- 2007 Pfizer. A9001265. Statin-induced myalgia.
2004- 2005 Bristol Myers Squibb. BMS CV131-185. HTN Moderate.
2004 Wyeth. WYTH-EAA-090. Diabetic Neuropathy
2004- 2005 Takeda. TAK 01-04-TL-475-011. Hypercholesterolemia
2004- 2007 Takeda. TAK 01-04-TL-475-002. Hypercholesterolemia
2004- 2005 Takeda. TAK 01-03-TL-536-002HTN. Hypertension
2004- 2007 Scios. SCIOS-FUSION II. Heart Failure – Natrecor infusion
2004- 2006 CV Therapeutics. CVT3036 MERLIN. Acute Coronary Syndrome
2004- 2005 Bristol Myers Squibb. BMS-CV131-176. HTN severe
2004 Amgen. AMG-20010184 TREAT. Reduce cardiovascular events
2004- 2006 Otsuka. OTSK-EVEREST. CHF
2004- 2006 Pfizer. PFI-A5091018. Mixed dyslipidemia
2004- 2006 Pfizer. PFI-A6141078. Heart Failure (LVSD)
2004- 2005 Angiogenix. ANG-ACCLAIM 01. Angina
2004- 2005 Alteon. ALT-711-0320. HTN
2004- 2005 CV Therapeutics. CVT5132. Nuclear imaging
2004- 2006 Otsuka. OTSK- SALT 2. Hyponatremia
2004- 2005 King Pharmaceuticals. KIN-VISION302. Spect
2004 Novartis. NOV-CCIB002I2301. HTN
2004- 2006 AstraZeneca. AZ-GALLEX 6. Diabetes (extension)
2004 Merck. MK-024 (MK-431). Diabetes
2004- 2006 AstraZeneca. AZ-GALLANT 6. Diabetes
2004- 2006 Novartis. NOV-CLAF237A2305 ext. Diabetes
2004- 2006 Novartis. NOV-CLAF237A2304 ext. Diabetes
2004 Conjuchem. CONJ-DM100-102. Diabetes
2004-2006 Novartis. NOV-CLAF237A2303 ext. Diabetes
2004-2006 Novartis. NOV-CLAF237A2303. Diabetes
2004-2006 Ortho-McNeil. ORMC-CAPSS-316. Migraine.
2004-2005 Ortho-McNeil. ORMC-CAPSS-295. Extension of CAPSS 276 Migraine
2004-2006 Regeneron. REG-IL1T-RA-0408. Rheumatoid Arthritis
2004-2005 Scios. SCIOS RA-469 (B009). Rheumatoid Arthritis
2004-2006 Forest. FOR-MLN-MD-02. Fibromyalgia
2004-2005 Ortho-Biotech. ORBIO PRO3-33-055. RA/Anemia
2004-2005 Takeda. TAK 01-03-TL-715-005. Rheumatoid Arthritis
2004-2005 Scios. SCIOS-RA-469 (B007). Rheumatoid Arthritis
2004-2005 Elan Pharmaceuticals. ELAN 251. RA ext to 201
2004-2005 Elan Pharmaceuticals. ELAN 201. RA
2004-2005 Johnson &Johnson. J & J 2001 OA. Pain – OA of knee
2004-2005 Berlex. Berlex Hormone therapy. Hormone therapy in HTN women
2004-2005 Galen Holding. GAL-10503. Oral contraceptive
2004 Pfizer. PFI-A6131007. Extension to adolescent w/ anxiety/panic disorder
2004 Pfizer. PFI-A6131004. Adolescents w/ Anxiety or panic disorder
2004 Pfizer. PFI-A6131002. Adolescents w/ panic disorder
2004-206 Guidant Corp. GUID-CAPTURE. Acculink stent and Accunet system
2004-2005 Ortho-Biotech. ORTBIO 026. Anemia in elderly patients
2004-2005 Ortho-Biotech. ORTBIO 025. Idiopathic anemia in elderly patients
2004 Peninsula. PEN-DORI-05. Complicated lower UTI
2004-2006 Bristol Myers Squibb. BMS-CV168-048. Diabetes
2004-2005 Novartis. NOV-CLAF237A2309. Diabetes
2004-2006 Novartis. NOV-CHTF919D2301. Female dyspepsia
2004-2005 Serono. SER-24979 Psoriasis. Psoriasis
2004-2006 Novartis. NOV-CVAS489A2316. HTN and Hypercholesterolemia
2004-2005 Pfizer. PFI-A3471109. ACL repair- post-op pain
2004-2006 Novartis. CSPP100A 2302. HTN
2004-2005 Novartis. NOV-CHTF919G2203. Diabetic Gastropathy
2004-2006 Novartis. CSPP100A 2203. HTN
2003-2005 Sepracor. 091-026. COPD
2003-2004 Merck. 025-01. Diabetes
2003-2004 Bristol-Myers Squibb. CV168-025. Diabetes
2003-2006 Organon/Sanofi. P64720. (AMADEUS). Prevention of thromboembolic events with
atrial fibrillation
2003-2004 Ortho-McNeil. CAPSS-276. Chronic Migraine
2003-2005 GlaxoSmithKline. PAA20001. Low HDLc, mild-moderate triglycerides, and normal low-
density lipoprotein cholesterol
2003-2004 Sanofi/BMS. L8829(CV131-170). Hypertension
2003-2006 GlaxoSmithKline. ARI40006. Reduction of risk of biopsy-detectable prostate cancer
2003-2006 AstraZeneca. 4522IL/0106. Hypercholesterolemia and coronary heart disease
2003-2003 Sanofi. EIV7920 (CAMPER) Maintaining patency of lower limb arteries after
angioplasty
2003-2004 Myogen. MY-023 (EMPOWER). CHF
2003-2004 Forest Laboratories. SCT-MD-027. Major depressive disorder
2003-2004 Forest Laboratories. SCT-MD-031. Generalized anxiety disorder
2003-2004 Merck. 071. Osteoarthritis
2003-2006 Eli-Lilly. F1J-MC-SBBO. Mixed Urinary Incontinence in women
2003 Wyeth. 3074A1-307-WW. Serious infections
2003-2005 Biosante. EST005. Vasomotor symptoms and vulvovaginal atrophy in
postmenopausal females
2003-2004 KOS. MA-03-010401. (TROPIC). Intermittent Claudication
2003-2006 Atherogenics. AGI-1067-042 (ARISE). CAD
2003-2006 Takeda. 01-01-TL-OPI-516. (PERISCOPE). Coronary atherosclerotic disease as
measured by intravascular ultrasound
2003-2004 Sanofi. L-8445. Osteoarthritis/Insomnia
2003-2005 Amylin. 2993-120. Type 2 Diabetes
2003-2005 GlaxoSmithKline. 49653C/325. Type 2 Diabetes
2003-2006 Merck. 072. Rheumatoid Arthritis
2003-2004 Takeda. 01-02-TL-375-025. Elderly with chronic Insomnia
2003-2004 Takeda. 01-02-TL-375-020. Adults with chronic insomnia
2002-2004 Esperion. ETC-588. Acute Coronary Syndrome
2003-2005 Novartis. VAA489A2201. Hypertension
2003-2005 Novartis. VAA489A2201 E01. Extension Study. (Hypertension)
2003-2005 BMS. CV181-008. Diabetes.
2003-2004 Celgene. D-MPH-COG-002. Fatigue and neurobehavioral impairment related to
chemotherapy in adult cancer patients
2003 Biomarin. NTL-06. Coronary artery bypass graft surgery
2002-2004 Yamanouchi. YM087-CL-071. Decompensated chronic heart failure
2003-2004 Pfizer. A1481132. Determination of highest dose of GTN that can be administered in
men with CAD
2003 Abbott. M01-393. CHF
2003-2004 Eli Lilly. H8O-MC-GWAA. Diabetes
2003 Sankyo. CS-011-202. Diabetes
2003-2005 Merck 010. Diabetes
2003-2004 Sigma Tau Research. ST-98-301. Intermittent claudication/Diabetes
2003-2005 Alteon. ALT-711-0215. (SAPPHIRE) Systolic pressure improvement (extension study)
2003-2008 AstraZeneca. 4522US/0011. (JUPITER). Low LDL (C – reactive protein)
2003 Novartis. SPP100A2201. Mild to moderate essential hypertension
2003-2005 GlaxoSmithKline. 46653/330. Chronic plaque psoriasis
2002-2003 CCIB002H2303. Novartis. Hypertension
2002-2005 XRP4563C/3501. Aventis. Extended VTE prophylaxis in acutely ill medical patients
with prolonged immobilization
2002-2003 20010240. Amgen. Hyperparathyroidism of End-stage Renal Disease
2002-2003 146-301HD. Andrx Lab. Hypercholesterolemia
2002 4522US/0003: AstraZeneca: Achieving NCEP ATP III LDL-C Goals in High-risk
Subjects with Hypercholesterolemia in the Managed Care Setting
2002-2003 4522US/0002: AstraZeneca: hypercholesterolemia in African American Subjects
2002-2003 NN622-1346: Novo Nordisk. Type 2 Diabetes
2002-2003 NN622-1347: Novo Nordisk. type 2 Hypertriglyceridemic Diabetic subjects
2002-2003 2000099: Proctor & Gamble/Alexion. All cause mortality and myocardial infarction in
patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass
2001-2003 TOPMAT-MIGR-001: R.W.Johnson. Migraine
2001-2003 M100240/2004: Mitsubishi-Toyko mild-to-moderate essential hypertension
2001-2003 SAS30021: GlaxoSmithKline. Symptomatic pediatric subjects (4-11 years) with asthma
2001-2003 A1651008: Pfizer. Major depressive disorder and associated somatic symptoms
2001-2003 A1651009: Pfizer. Major depressive disorder and associated somatic symptoms
2001-2003 CVAH631AUS01: African American patients with Mild to Moderate Hypertension
2001-2002 Pfizer 1027-018-006: hypercholesterolemia
2001-2003 Merck 023-00: (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or
CHD risk equivalent strata low-density lipoprotein cholesterol (LDL-C) target level
2001-2003 Novartis CCIB002FUS08: systolic blood pressure and pulse pressure in patients with
systolic hypertension
2001-2003 AMGEN, AMG 073 20000172: secondary hyperparathyroidism of end stage renal
disease treated with hemodyalisis
2001-2003 Pfizer A3841001 (AVALON): simultaneous hyperlipidemia and hypertension
2001-2002 A1601072-6030: quantitative coronary angiography
2001-2004 Sanofi EFC4788: American-Australian-African trial atrial fibrillation or flutter patients
for the maintenance of Sinus rhythm (ADONIS)
2001 Astra Zeneca 4522IL/0068: Type IIa and IIb hypercholesterolemia
2001-2002 CV 138-061, IND#52,837: Type 2 Diabetes Mellitus
2001-2002 RWJ-241947-DIAB-002: Type 2 diabetic subjects
2001-2001 B00.CT3.012.DIL.G99: chronic, stable, exercise-induced angina
2001-2002 NN622-1341 Type 2 diabetic subjects
2001-2003 SK&F 105517/347: hypertensive patients with Type II Diabetes Mellitus
2001-2003 EFC4736: obese patients with Type 2 Diabetes
2001-2006 CDJN608B2302: prevention of diabetes and cardiovascular outcomes in subjects with
impaired glucose tolerance (IGT)
2001-2002 INS1-DM-28: to achieve adequate glycemic control with diet and exercise
2001-2003 CCIB002FUS06: Novartis Pharmaceuticals hypertension in an African-American
population with Type 2 Diabetes
2001-2002 A2581042 NASDAC Hypercholesterolemia
2001 OCTAVE: cardiovascular treatment assessment
2001-2003 EFC4735: obese patients with untreated dyslipidemia
2001-2003 BN02-C007: Type 2 Diabetes Mellitus
2001-2002 Pfizer. A1481084: erectile dysfunction and congestive heart failure
2001-2002 Pfizer. A1481085: erectile dysfunction and coronary artery disease
2001-2002 Bayer. FACTOR: type 2 diabetic men and women
2001-2002 Ajinomoto. ATA-201: intermittent claudication due to peripheral arterial disease
2001-2002 SmithKline. 207499/156: chronic obstructive pulmonary disease (COPD)
2001-2003 Amgen: 20000223: rheumatoid arthritis
2001-2002 Discovery Therapeutics: DTI-0009/003: atrial fibrillation
2001-2002 Pharmacia/Searle: NB4-00-02-009: primary hypercholesterolemia
2001-2003 Merck: 005: primary hypercholesterolemia
2001-2002 Biovail: B00.CT3.011.DIL.G99: essential hypertension
2001-2005 AstraZeneca: ZD4522IL/0065: hypercholesterolemia.
2001-2002 Pfizer: 1011-056: type IIa and IIb dyslipidemia
2001-2002 Scios: 704.341: acutely decompensated CHF
2000-2002 Pfizer: A3071005: low levels of high density lipoprotein cholesterol
2000-2002 Pfizer: A3071006: low levels of high density lipoprotein cholesterol
2000-2002 Pfizer: A3071007: with or without low levels of high density lipoprotein cholesterol
2000-2001 Bristol Myers Squibb: CV137-120: hypertension
2000-2001 Biovail: B00.CT3.012.DIL.G99: chronic stable exercise-induced angina
2000-2003 AstraZeneca: 233(SPORTIF V): atrial fibrillation
2000-2001 Roche: WV16193: influenza in households
2000-2001 Merck: 024-02: Rheumatoid Arthritis Patients
2000-2001 Pfizer. 1027-004: low HDL-C and either normal or elevated triglycerides
2000 Pharmacia. M/2020/0047: major depressive disorder
2000-2001 Bayer. CHORUS 100253-34: end stage renal disease (ERSD) new to hemodialysis
2000 SmithKline. CHARM 278817/003: Hyperlipidemia after menopause
2000-2001 R.W. Johnson. RWJ-241947-DIAB-002: Type 2 diabetics
2000-2001 Parke Davis. 376-400-421-069: breakthrough bleeding profiles of women on Femhrt®
or Prempro
2000-2001 Pfizer. 1025-007: euvolemic or hypervolemic Hyponatremia
2000 Sanofi. EFC2441 acute symptomatic deep vein thrombosis (DVT)
2000-2002 AstraZeneca.237: prevention of venous thromboembolism following total hip
arthroplasty
2000 AstraZeneca. 236: prevention of venous thromboembolism following total
knee arthroplasty
1999-2003 Shire LAM-IV-307: chronic renal failure patients receiving hemodialysis
1999-2000 Pfizer. A0661013: treatment of acute bacterial exacerbation of chronic bronchitis
1999-2001 SmithKline. Ariflo (SB 207499)041: chronic obstructive pulmonary disease (COPD).
1999-2003 Amgen 990757: Rheumatoid Arthritis
2000-2004 Amgen 990145: rheumatoid arthritis
1999-2001 AstraZeneca 9188IL/0155: Asthma
1999-2001 SmithKline. BRL49653/048: Type 2 diabetes Mellitus (<2years).
1999-2000 Searle. N91-99-02-061: rheumatoid arthritis
1999-2001 Searle. N91-99-02-067: rheumatoid arthritis
1999-2001 Searle. IE3-99-02-020: black and white hypertensive patient
1999-2001 Searle. IE3-99-02-022: elevated systolic blood pressure
1999-2001 Searle. IE3-99-02-035: heart failure following acute myocardial infarction
1999 Hoffmann LaRoche. WV15978: A double blind stratified randomized placebo
controlled study of Ro 64-0796 (also known as GS4104) in the treatment of influenza infection
in elderly adults
1999-2000 Merck. 121-00: chronic low back pain
1999-2000 Novo Nordisk.NN304-1167: type 2 diabetes
1999-2000 SmithKline Beecham. 29060/677: premenstrual dysphoric disorder
1999-2001 GlaxoWellcome. PPA30013: Type 2 diabetes mellitus
2000-2001 GlaxoWellcome. PPA30014: Type 2 diabetes mellitus.
1999-2006 AstraZeneca. 4522IL/0034: hypercholesterolemia
1999-2000 Novo Nordisk. AGEE 2022: Type 2 diabetes
1999-2001 Novo Nordisk. AGEE 2064: type 2 diabetes
1999-2000 Merck. 180-00/ZOC467: Acute Coronary Syndrome Patients
1999 Genetech.S0826g: Acute Myocardial Infarction
1999-2002 Otsuka. 196-98-201-01: intermittent claudication secondary to peripheral arterial
disease
1999 Otsuka. 21-98-213-01: intermittent claudication secondary to peripheral
arterial disease
1999 Novartis. CXUO320 0205: primary hypercholesterolemia
1999-2002 Hesparion. AC-052-302 (ENABLE 2): chronic heart failure
1999-2001 Shire. LAM-IV-302 –St. Aug: chronic renal failure patients receiving hemodialysis
1999-2002 Novartis.CDJN608-0116: type 2 diabetes mellitus patients with minimally elevated
fasting plasma glucose levels
1999-2000 GlaxoWellcome. PPA30002: Type 2 diabetes mellitus who are inadequately controlled
on a maximum dose of Metformin
1999-2000 CV Therapeutics. CVT3034: chronic stable angina pectoris
1999-2000 AstraZeneca 4522IL/0031: severe hypercholesterolemia
1999-2000 AstraZeneca 4522IL/0033: hypercholesterolemia
1999-2000 AstraZeneca 4522IL/0029: type Iib and IV hyperlipidemia
1999-2000 Schering-Plough. Rhinitis: P00218-8 perennial rhinitis
1999-2001 Parke Davis. ACATPVD: 1011-19. Peripheral arterial disease
1999-2000 Purdue OA: BP99-0203. Osteoarthritis of the hip or knee
1999-2000 SmithKline. Ariflo: (SB 207499)039. Chronic obstructive pulmonary disease (COPD)
1999 Pharmacia & UpJohn. CIS-Afib: M/7555/0010. Persistent atrial fibrillation
1999-2001 Zeneca. CESNA III: 1518US/0008:0007). Treatment of black subjects with hypertension
1999-2001 Immunex. TNF: 16.0021. Chronic heart failure
1999-2000 Otsuka. OPC-PVD: 21-98-213-01. Intermittent claudication secondary to peripheral
arterial disease
1999 Purdue. KD98-0602: type 2 diabetic patients
1999-2001 CV Therapeutics. CVT3033: chronic stable angina pectoris
1999-2000 BAYER OA: 100011 (BAY 12-9566). Mild to moderate osteoarthritis of the knee, over 3
years
1999-2000 ZENECA: 4522IL/0028. Hypercholesterolemia
1999-2001 SmithKline. PRESTO: BRL00952AA/004. Prevention of Restenosis with Tranilast and
its Outcomes: A placebo-controlled trial
1999 Novo Nordisk. Insulin: NN304-2006. type 2 diabetic patients
1999-2000 KOS Pharm. KOS 2: MA-98-010414. Hypercholesterolemia
1999-2001 SmithKline. BRAVO: BRL 214857/030. Blockade of the FP IIB/IIIA Receptor to Avoid
Vascular Occlusion
1999-2003 Parke Davis. LONA 011: 1025-011. euvolemic or hypervolemic hyponatremia
1999-2003 Parke Davis. LONA 06: 1025-06. euvolemic or hypervolemic hyponatremia
1999-2000 Parke Davis. LONA 05: 1025-05. nonhypovolemic hyponatremia
1999-2000 KOS Pharm. KOS: MA-98-010406. Hypercholesterolemia
1999 Johnson & Johnson. Meal Study: MK-0208-128-00. Heartburn symptoms
1998-1999 Moxcon B3N-MC-EUBC (a)/743 congestive heart failure
1998-1999 Parke Davis. (1025-03-05 euvolemic hyponatremia or CHF patients with hypervolemic
hyponatremia
1998-2001 Proctor & Gamble. 1998017: symptomatic atrial fibrillation/flutter and/or
symptomatic paroxysmal supraventricular tachycardia
1998-2000 Merck. (MK-088-01) rheumatoid arthritis
1998-1999 Parke Davis. (1025-2-05). hypervolemic hyponatremia
1998-1999 Roche. (M76001). influenza infection
1998-1999 Purdue. (OC98-0203). Post-Op pain
1998 Eli-Lilly.(B7A-MC-MBBS). Diabetic peripheral arterial disease
1998 Searle. (N49-98-02-102) osteoarthritis or rheumatoid arthritis
1998-2001 Sanofi. CURE (EFC 3307) acute coronary syndrome (unstable angina or myocardial
infarction without ST segment elevation)
1998-1999 Sanofi (EFC2442). Prevention of deep vein thrombosis and symptomatic pulmonary
embolism after hip replacement or revision
1998-1999 Organon (095-002) prevention of deep vein thrombosis and symptomatic pulmonary
embolism after elective surgery or a revision
1998-1999 Allergan (190342-008). Glaucoma or ocular hypertension
1998-1999 Parke Davis. Challenge (981-400-320): hypercholesterolemic patients
1998-1999 NovoNordisk. (KLIM/USA/1/USA) hormone replacement therapy
1998 Novartis UXO-F356-E-00: mixed dyslipidemia
1998-1999 PARAGON B (BC15686): unstable angina/non-Q wave myocardial infarction
1998 Novartis.(XUO-353-E01) primary hypercholesterolemia
1998 Glaxo Wellcome. ENHANCE (PPA20005). Type 2 diabetes mellitus
1998-2000 Merck. UTI (021-002-025) Protocol # MK-0826. Complicated urinary tract infections in
adults
1998 Wyeth-Ayerst. (0927B2-926-US). Extension of redux-echo study to evaluate
patients exposed to anorexigens
1998-2003 GlaxoWellcome.(ARIB3003) benign prostatic hyperplasia.
1998 Otsuka. RESQ-X (25560S2737). Long-term, open-label, safety study of RS-
25560 in patients with congestive heart failure
1998-1999 KNOLL. MERIDIA (SB113). Obesity
1998-2000 Parke Davis. TROG CHF (991-107) Type II diabetes and congestive heart failure.
1998-1999 NOVA Diabetes (B-356-E-00) NIDDM inadequately controlled by diet
1998-2000 CESNA II (1518US/0004:0017) hypertensive subjects with ischemic heart disease
1998-2003 Novartis. VALUE (405) essential hypertension
1998-2000 Knoll.RAFT (P-85-AF) A Double-blind, placebo-controlled, randomized clinical trial of
slow release propafenone (Rythmol-SR) in the prevention of symptomatic recurrences of atrial
fibrillation
1998-1999 Novartis. LESCOL (XUO-F353-E-00) primary hyperlipidemia
1998 Study Coordinator: REDUX/Echo (0927A1-915) An echocardiographic
evaluation of patients exposed to anorexigens as compared to unexposed matched controls
1998-1999 CV Therapeutics. (CVT3031) chronic stable angina pectoris
1998-2000 SmithKline. COPERNICUS (MF4477/SB 287) severe chronic heart failure
1998 Parke Davis. (981-158) mixed dyslipidemia
1998-2000 Parke Davis. (ATORPET 981-121) progression of atherosclerosis as measured by PET
and stress echocardiography in patients with CAD
1997-2000 Novartis. Valsartan CHF (106) stable, chronic congestive heart failure
1997-1999 Tap Holdings. TAP (M96-598) rheumatoid arthritis patients
1997-1998 Parke-Davis. REZU (991-085) Type II diabetes mellitus (NIDDM) Patients
1997-2002 Study Coordinator: WIZARD (066-192-5022) incidence of CAD in subjects with
evidence of exposure to C. pneumoniae
1997-1998 Otsuka. REST (103-97-201) heart failure
1997-2000 Centeon. BERIPLAST (BI 91.021.3-2/3001) treatment of bleeding anastomosis sites in
surgical patients receiving PTFE bypass grafts to the common femoral artery
1997-1998 Wyeth Ayerst. FIBLAST (03062K1-300-US) acute stroke
1997-2002 Parke-Davis. ATORPVD (981-123) peripheral vascular disease
1997-1998 Parke-Davis. (981-228) hypercholesterolemic patients
1997-1998 Toray (USTRK-2/01) hyponatremia coincident with congestive heart failure
1997 SmithKline. Teveten (124) essential hypertension
1997-1998 Merck. (MK-075) moderate primary hypercholesterolemia
1997-1999 RPR ATLAST (RP54563Q-310) increased risk of stent thrombosis
1997-1998 Roche. RES-Q (2672) congestive heart failure
1997-2002 Glaxo Wellcome (ARIA 3002) progression of benign prostatic hyperplasia
1997-1998 Proctor & Gamble. (1997017) recent post-myocardial infarction patients at risk of
sudden death
1997-1998 Dupont.(DMP 754-010) coronary artery disease
1997-1998 Parke Davis (ACAT 1011-05-09) hypercholesterolemia
1997 Parke Davis (ACAT 1011-03-09) hypercholesterolemia.
1997-1998 Otsuka (103-95-202) heart failure
1997 Parke Davis. (56-97-201) coronary artery disease (CAD), diabetic patients, and
healthy control subjects
1997-1998 Bristol Myers Squibb. (CV137-012-014) heart failure
1997-2001 Bristol Myers Squibb. (CV137-018) heart failure
1997 Scios. (704.326) decompensated CHF
1997-1998 Searle. EPLERENONE (EE3-96-12-010) mild to moderate hypertension
1997-1998 Searle. EXCITE (IG7-96-02-017) coronary angioplasty or stent placement
1997-1998 GUARDIAN (HOE642A/3001) at risk of myocardial necrosis due to acute coronary
syndrome related to the disease process or to an interventional cardiac procedure
1997-98 Sanofi (DRI-2643) prevention of deep vein thrombosis after elective total hip replacement
1997 Hoffmann LaRoche. MIBNIFX LRA#4351 & JRB#4208. Drug Usage Plans: For compassionate
use cases – Posicor®
1997-1998 Proctor & Gamble. SVA3/3X (1996033 & 34) symptomatic atrial fibrillation/flutter
and/or symptomatic paroxysmal supraventricular tachycardia and extension protocol
1996-2001 Searle. CONVINCE (I26-96-12-011) Clinical Protocol for Controlled Onset Verapamil
Investigation of Cardiovascular Endpoints
1996-1998 Pfizer. SADHART (R-0511) major depression after myocardial infarction
1996-1997 Otsuka. PVD4 (21-96-202) intermittent claudication secondary to peripheral vascular
disease
1996-1997 Searle. SANG (N26-94-02-004). chronic stable angina
1996-1997 Hoffmann LaRoche MIBNIF (NR15195A) chronic stable angina pectoris
1996-1997 Parke Davis (981-160) Extended access treatment protocol for the use of atorvastatin
in patients who participated in protocols 981-26, -62, -69, -70, and -77
1996-1997 Parke Davis TROG (991-084). Noninsulin dependent diabetes mellitus (NIDDM)
patients requiring insulin
1996-1997 Wyeth Ayerst. WAR (820-A-330-US/Ca) essential hypertension
1996 Marion Merrell Dow. BERAPROST (201129PR0008). intermittent claudication
1996-2001 Merck. LIFE (133/COZ 368 & 236). Reduction of morbidity and mortality in
hypertensive patient with left ventricular hypertrophy
1996-2001 Merck. LIFE Echo Sub Study. Echocardiographic left ventricular mass change and
prognosis in hypertension: Effect of Losartan and Atenolol
1996-1997 Dupont DMP 504 (006). hypercholesterolemic patients
1996 Dupont DMP 504 (005). Primary hypercholesterolemia
1996-2000 Pfizer. PRAISE-2 (053-185). Congestive heart failure
1996 DU (M95-282). Eradication of Helicobacter pylori
1996-1998 Proctor & Gamble. SVA2/2X (1995115 & 16). Prophylactic treatment of symptomatic
atrial fibrillation/flutter and/or symptomatic paroxysmal supraventricular tachycardia.
1996 SmithKline Beecham. CARVEDILOL (105517). Chronic congestive heart failure
(NYHA Class II-IV)
1996-1997 Amersham. SMAC (MPI PR96-303). Rule out myocardial infarction patients who
present with chest pain without ST segment elevations, who receive SPECT Tc-99m-
Tetrofosmin perfusion imaging, and are randomized to angioplasty/early exercise testing vs.
conventional therapy
1996 Lorex. (LES02) Assessment of the efficacy and safety of eliprodil in patients
with acute ischemic stroke
1996-1997 Roche. MACH 1 (BC-14808) chronic heart failure (NYHA Class II-IV)
1996-1997 Otsuka. (OPC-103-93-201A & 202A). decompensated heart failure
1996-1997 Searle. ORBIT (NG7-96-12-050). Stable or unstable angina or hospitalized for a recent
myocardial infarction and have completed coronary revascularization
1996-2001 Otsuka. VESTX (22-95-209) Long-Term extension of VEST 22-94-201 trial
1996-1997 Merck. RENAAL (147-00). Noninsulin dependent diabetes mellitus and nephropathy
1996 Study Coordinator: PRIME (H3M-MC-EQAC) Efegatran versus Heparin for acute myocardial
infarction
1995-1996 Otsuka. (21-95-201). intermittent claudication secondary to peripheral vascular
disease
1995-1996 Wyeth Ayerst.(820-A-305-US) essential hypertension
1995-2000 TEE – The effect of lipid lowering therapy using simvastatin on the progression and
morphology of protruding atheroma of the thoracic aorta identified by transesophageal echo –
a pilot study
1995-1996 Study Coordinator: VEST (22-94-201). Heart failure
1995-1996 VEST Exercise Sub Study – cardiorespiratory fitness in heart failure patients enrolled in
a drug intervention trial
1995-1996 Otsuka. (21-94-203) – intermittent claudication secondary to peripheral vascular
disease
1995-1996 Hoffmann LaRoche. MIB (NC14983A) chronic stable angina pectoris
1995-1999 Otsuka. Cilostazol (21-91-201) intermittent claudication secondary to chronic
occlusive arterial disease
1995-1996 Otsuka. (21-94-201). intermittent claudication secondary to peripheral vascular
disease
1995-1996 Parke Davis. (981-70) coronary heart disease
1995-1996 Parke Davis. (981-69) coronary heart disease and/or peripheral vascular disease
1995-1999 Parke Davis. Endocarditis (960-017) endocarditis
1995-2002 Parke-Davis/Pfizer. (981-53) hypercholesterolemic patients with coronary artery
disease at risk of adverse outcomes.
1995-1996 Study Coordinator: ESSENCE (RP 54563-303). Non-Q-wave coronary events (unstable
angina an non-Q-wave MI)
1995-1996 Study Coordinator: ENOX (RP54563-307) prevention of deep vein thrombosis.
1995-1996 Proctor & Gamble. AZIM: (1995010). Symptomatic atrial fibrillation/flutter and/or
symptomatic paroxysmal supraventricular tachycardia
1994 Study Coordinator: MTRA – chronic stable angina
1994 Novartis. Valsartan – hypertensive patients inadequately controlled with
Valsartan 80 mg once daily
1994 (SR 47436) (irbesartan) for the treatment of hypertension.
1994-1996 Study Coordinator: MK-383 (011-132) unstable angina/non-Q-wave infarction
1994-1997 Bristol Myers. (CV131-029) hypertension.
1994 Study Coordinator: Multicenter double blind study to compare the efficacy
and tolerability of 10 mg, 20 mg, and 40 mg doses of Lovastatin versus 20 mg and 40 mg doses
of fluvastatin in the treatment of patients with hypercholesterolemia
1994-1996 Parke Davis. (981-042) elevated triglycerides
1993-1995 AFIB – Treatment of Atrial Fibrillation and PSVT with bidisomide.
1993 Cardizem CD – The safety and efficacy of Cardizem CD for the treatment of
stable angina pectoris
1993-1996 Dupont. CARS (DuP 647-003-199). Prevention of reinfarction, cardiovascular death,
and stroke in post-myocardial infarction patients
1993 Fantofarone – Evaluation of Fantofarone in stable angina.
1993-1994 Parke Davis. Fluvastatin – Treatment of hypercholesterolemia in a clinical practice
setting.
1993-1995 Parke Davis. Atorvastatin (981-08). Elevated LDL-cholesterol
1992-1994 Study Coordinator: A.S.A.P. – Treatment of Stable angina with Amlodipine
1992-1997 Study Coordinator: Atlas – Treatment of Class III and IV congestive heart failure with
Lisinopril
1992-1994 Study Coordinator: Nitro-Dur – Treatment of post myocardial infarction patients with
Nitroglycerin
1992-1993 Study Coordinator: Profile – Treatment of class III and IV congestive heart failure
1992-1995 Study Coordinator: Magnesium – Treatment of atypical chest pain and palpitations
with supplemental Magnesium
1991-1992 Study Coordinator: Sotalol – The treatment of life threatening ventricular arrhythmias
1991-1992 Study Coordinator: Quinapril – The treatment of class II and class III congestive heart
failure
1991-1992 Study Coordinator: Zestoretic – The treatment of mild to moderate hypertension
1991-1992 Study Coordinator: Thrombolytic Registry – Evaluation of the treatment of myocardial
infarction: thrombolytic vs. medical management.
1990-1991 Study Coordinator: MILRINONE – Class II and Class IV CHF failure survival study.
1990-1991 Study Coordinator: ASIST – Atenolol Silent Ischemia Trial
1989-1991 Study Coordinator: TIMI IIIB – Comprehensive Management of unstable angina and
non Q-wave myocardial infarction (roles of TPA and revascularization)
1990-1991 Study Coordinator: TRANSDERM NITRO 40 CM2 – Comparison of 1 TDN 40 CM2 and two TDN
20 CM2 adhesive properties and angina response
1990-1992 Study Coordinator: LOPID-MR – Efficacy and safety of Lopid modified release form
Study Coordinator: MEVACOR – Management of non familial primary
hypercholesterolemia
1986-89 Study Coordinator: Q-MED MONITOR – Ambulatory monitoring for silent ischemia
1985-86 Study Coordinator: TRANSDERM NITROGLYCERIN – Comparison of adhesive properties of two TDN Systems

RESEARCH TRAINING:
9/10/2021 FibroScan 530 Training
4/8/2021 OSHA Bloodborne Pathogens Training
4/6/2021 NIDA Good Clinical Practice
6/25/2020 OSHA Bloodborne Pathogen Training
4/2/2020 Virtual Trial Capable
3/9/2020 ERT eLearning SYN SP-1011-003 eCOA Study Specifics
10/21/2019 Mayo Clinic IATA Training
4/16/2019 Pfizer Safety Reporting (non-CPT) version 2.0
4/8/2019 CITI Good Clinical Practice
4/2/2019 Janssen Investigator Safety Training v.4 dated 15NOV2017
11/3/2018 TransCelerate GCP Certificate
11/2-3/2018 Encore Research Group Clinical Research Training for Physicians
4/18/2018 Basic Life Support recertification
4/26/2017 Pfizer Impala Training, version 3.0
12/24/2013 InForm GTM 5.5 for Site Users by Oracle
10/15/2013 CITI Good Clinical Practice Course
9/20/2013 IATA 1.5, shipping of: Category A, Infectious Substance AffectingHumans and Category B, Biological Substance presented by Mayo Clinic
2013 Section 4 of Training & Certification module for Placement and Removal of the
Intarcia ITCA 650 Investigational Product
3/20/2013 Acne Lesion Counter Training
12/5/2011 Inform version 4.6 Training
7/19/2011 CITI Good Clinical Practice Course (Reference # 5981348)
5/3/2011 Completion of Mayo Clinic Training for the handling/offering for
transportation of dangerous goods
10/2010 Inform version 5.0 Training
1/31/2010 InForm v4.6 – Data Entry and Signature for GSK SOLID TIMI 52
1/29/2010 Good Clinical Practice for GSK SOLID TIMI 52
12/2/2009 InForm v4.6 Gap Training for GSK SOLID TIMI 52
11/20/2009 November 2009 SOLID-TIMI 52 Investigator Meeting – Day 2
11/19/2009 November 2009 SOLID-TIMI 52 Investigator Meeting – Day 1
11/2009 Clinical Investigator Training sponsored by JaxResearch
5/19/2009 Completion of NIH “Protecting Human Research Participants” Web training
5/2009 IATA Training by Saf-T-Pak
2006 HAZMAT Training – JCCR
2004-2007 Clinical Investigator Training – Orlando, Philadelphia, Ponte Vedra Beach
2002 Good Clinical Practices Training – Merck
AIDS/HIV Training